epirubicin has been researched along with Carcinoma, Anaplastic in 126 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (3.97) | 18.7374 |
| 1990's | 38 (30.16) | 18.2507 |
| 2000's | 45 (35.71) | 29.6817 |
| 2010's | 36 (28.57) | 24.3611 |
| 2020's | 2 (1.59) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Ashmawy, GM; El-Ashmawy, NE; El-Kady, AY; Khedr, EG | 1 |
| Akashi, H; Ando, K; Furuya, D; Kawada, H; Kawai, H; Ogawa, Y; Suzuki, R | 1 |
| Bernard-Marty, C; Dalenc, F; de Lafontan, B; Dulguerova, P; Guerrero, D; Guyonnaud, J; Levasseur, N; Levecq, JM; Massabeau, C; Ranc Royo, AL; Ribet, V; Rossi, AB; Salas, S; Sarda, C; Sibaud, V | 1 |
| Liu, Y; Shang, D; Song, B | 1 |
| Ahmed, M; Amir, M; Hassan, S; Khan, K; Khokhar, N; Nasir, H | 1 |
| Funakoshi, T; Hirai, I; Kawakami, Y; Nakamura, Y; Tanese, K | 1 |
| Gong, Y; Hao, S; Jiang, YZ; Jin, X; Ren, YX; Shao, ZM; Ye, FG | 1 |
| Chan, MW; Chen, LG; Chen, SY; Hsieh, HY; Hsu, CD; Lin, MY; Lu, CC; Shen, CH | 1 |
| Aitini, E; Bighin, C; Bisagni, G; Clavarezza, M; De Placido, S; Del Mastro, L; Durando, A; Galli, A; Garrone, O; Levaggi, A; Restuccia, E; Saracchini, S; Scalamogna, R; Turazza, M | 1 |
| Aittomäki, K; Blomqvist, C; Carpén, O; Fagerholm, R; Heikkilä, P; Heikkinen, T; Khan, S; Korpela, T; Nevanlinna, H | 1 |
| Fujimoto, M; Fujisawa, Y | 1 |
| Blaskowsky, LS; Enzinger, PZ; Hong, TS; Kwak, EL; Mamon, HJ; Mullen, JT; Ryan, DP; Schoenfeld, JD; Wo, JY | 1 |
| Abdel-Wahab, M; Abubaker, S; Afiane, M; Benjaafar, N; Bourque, JM; Chansilpa, Y; El-Gantiry, M; Elattar, I; Levendag, P; Rosenblatt, E; Vikram, B | 1 |
| Evangelatov, A; Mladenov, N; Pankov, R; Petkova, M; Skrobanska, R; Yordanov, G | 1 |
| Huang, J; Li, B; Li, Q; Shen, J; Wang, J; Yuan, Y; Zheng, Y; Zou, R | 1 |
| Cosio, S; Fanucchi, A; Gadducci, A; Lanfredini, N; Menichetti, A; Notarnicola, M | 1 |
| Fujiwara, Y; Hashimoto, J; Hirakawa, A; Kodaira, M; Koizumi, F; Komori, O; Nakatochi, M; Okuma, HS; Shimizu, C; Tamura, K; Yamamoto, H; Yonemori, K; Yunokawa, M | 1 |
| Hou, H; Li, T; Liu, C; Liu, D; Liu, K; Lv, H; Wang, G; Zhang, C; Zhang, X; Zhou, N; Zhu, J | 1 |
| Kinoshita, S; Shimada, T; Takeyama, H; Uchida, K | 1 |
| Lin, HH; Lin, JN | 1 |
| Gennatas, K; Gennatas, S; Michalaki, V | 1 |
| Bagnardi, V; Balduzzi, A; Bertolini, F; Cardillo, A; Colleoni, M; Goldhirsch, A; Mancuso, P; Montagna, E; Orlando, L; Scarano, E; Torrisi, R; Veronesi, P; Viale, G | 1 |
| Capasso, I; Comella, G; Comella, P; D'Aiuto, G; D'Aiuto, M; Di Bonito, M; Frasci, G; Iodice, G; Lastoria, S; Montella, M; Oliviero, P; Petrillo, A; Ruffolo, P; Santangelo, M; Siani, C; Vizioli, L | 1 |
| Duchek, M; Hellsten, S; Hellström, P; Jahnson, S; Johansson, R; Malmström, PU; Mestad, O | 1 |
| Babjuk, M | 1 |
| Bidard, FC; Brain, E; de Cremoux, P; Delaloge, S; Giachetti, S; Marty, M; Mathiot, C; Pierga, JY | 1 |
| Arslan, C; Kilickap, S | 1 |
| Améri, A; Béroud, R; Cret, C; Koumakis, E; Meppiel, E; Stefanizzi, S | 1 |
| Çal, Ç; Özen, H; Şahin, H; Tanıdır, Y; Türkeri, L | 1 |
| Ben Salah, H; Boudawara, T; Daoud, J; Frikha, M; Gargouri, R; Ghorbel, A; Ghorbel, L; Karray, H; Khabir, A; Toumi, N | 1 |
| Kostova, I; Stancheva, T; Zaprjanova, P | 1 |
| Hudis, CA; Morris, PG | 1 |
| Barbanti, G; Bargagli, G; Chiriacò, G; Conca, R; De Rubertis, G; Fiaschi, AI; Francini, E; Francini, G; Manganelli, A; Pascucci, A; Petrioli, R; Ponchietti, R | 1 |
| Ahlgren, J; Andersson, M; Bengtsson, NO; Bergh, J; Bjerre, K; Blomqvist, C; Edlund, P; Holmberg, SB; Jakobsen, E; Lindman, H; Mouridsen, H; Møller, S | 1 |
| Bergh, J; Brandberg, Y; Iiristo, M; Wiklund, T; Wilking, N | 1 |
| Athanassiou, H; Bobos, M; Ciuleanu, E; Ciuleanu, T; Dionysopoulos, D; Eleftheraki, AG; Fountzilas, G; Kalogera-Fountzila, A; Karayannopoulou, G; Markou, K; Misailidou, D; Nikolaou, A; Resiga, L; Samantas, E; Skarlos, D; Zaramboukas, T | 1 |
| Caris, CT; Hendricksen, K; Janzing-Pastors, MH; Lammers, RJ; Witjes, JA; Witjes, WP | 1 |
| Boidot, R; Bonnetain, F; Cadouot, M; Chevrier, S; Lizard-Nacol, S; Végran, F | 1 |
| Brandi, M; Colucci, G; Di Benedetto, A; Di Lauro, L; Filippelli, G; Foggi, P; Gebbia, N; Giannarelli, D; Giotta, F; Lopez, M; Massidda, B; Mottolese, M; Schittulli, F; Vici, P | 1 |
| Farkas, R; Horváth, OP; Kálmán, E; Kovács, G; Kövér, E; Pavlovics, G; Szalai, G; Tizedes, G; Zapf, I | 1 |
| Cottura, E; Dalenc, F; De Benedictis, E; Deslandres, M; Gianni, L; Gladieff, L; Govi, S; Locatelli, A; Messina, M; Roché, H; Zambetti, M | 1 |
| Baldi, A; Citro, G; Fanciulli, M; Spugnini, EP | 1 |
| Allegro, R; Altieri, V; Carrieri, G; Di Lallo, A; Morgia, G; Serretta, V | 1 |
| Amunni, G; Baroni, G; Pazzagli, M; Pinzani, P; Raspollini, MR; Taddei, A; Taddei, GL; Villanucci, A | 1 |
| Altun, M; Anacak, Y; Basaran, M; Bavbek, SE; Esassolak, M; Haydaroglu, A; Kaytan, E; Onat, H | 1 |
| Benedetti Panici, P; Borsellino, N; Citarrella, P; Di Marco, P; Fallica, G; Gebbia, N; Gebbia, V; Tirrito, ML; Valenza, R; Valerio, MR | 1 |
| Capotorto, AM; Da Prada, GA; Farris, A; Lelli, G; Martoni, A; Massidda, B; Pavesi, L; Pedrazzoli, P; Robustelli della Cuna, G; Zamagni, C | 1 |
| Buda, A; Colombo, N; Conte, PF; Floriani, I; Fossati, R; Mangioni, C; Ravaioli, A; Rossi, R; Torri, V | 1 |
| Boecker, W; Buerger, H; Euler, U; Kersting, C; Kiesel, L; Sonntag, B; Tio, J; Tulusan, AH; Wülfing, C; Wülfing, P | 1 |
| Costa, NM; Matos, E; Pardal, F; Pereira, H; Rodrigues, H | 1 |
| Ardizzoia, A; Barni, S; Biasioli, R; Freddi, E; Frontini, L; Grassi, MM; Lucani, L; Mandalà, M; Nosenzo, MA; Piazza, E; Pravettoni, A; Recalcati, A; Rezzani, C; Sala, R; Trabucchi, E; Villa, S; Visini, M | 1 |
| Arbion, F; Body, G; Brunereau, L; Chapiron, C; Denis, F; Desbiez-Bourcier, AV | 1 |
| Blishchenko, EY; Ivanov, VT; Kalinina, OA; Karelin, AA; Moiseeva, EV; Sazonova, OV; Vass, AA | 1 |
| Akiyama, F; Hisamatsu, K; Iwata, H; Kaise, H; Kuroi, K; Kurosumi, M; Kusama, M; Masuda, N; Nakamura, S; Ohno, S; Sato, Y; Shin, E; Takatsuka, Y; Toi, M; Tsuda, H; Yamazaki, K | 1 |
| Ambrogi, MC; Angeletti, CA; Basolo, F; Duranti, L; Fontanini, G; Lucchi, M; Mussi, A | 1 |
| Avril, N; Bader, M; Dose Schwarz, J; Hemminger, G; Jänicke, F; Jenicke, L | 1 |
| Douek, M; Tobias, J | 1 |
| Aguiar Bujanda, D; Aguiar Morales, J; Bohn Sarmiento, U; Cabrera Suárez, MA; Limeres González, MA; Pavcovich Ruiz, M | 1 |
| Barabás, J; Cséplo, K; Németh, Z; Szabó, G; Szigeti, K; Vaszilkó, M; Velich, N | 1 |
| Astudillo-De la Vega, H; Benitez-Bribiesca, L; Castillo-Medina, S; Malacara, JM; Murillo-Ortiz, B | 1 |
| Colleoni, M; Curigliano, G; Ghisini, R; Giovanardi, F; Goldhirsch, A; Intra, M; Luini, A; Maisonneuve, P; Peruzzotti, G; Pietri, E; Rocca, A; Veronesi, P; Viale, G | 1 |
| Kuge, H; Kuzumoto, Y; Morita, T | 1 |
| Audhuy, B; Bonneterre, J; Chollet, P; Clavère, P; Eymard, JC; Fargeot, P; Fumoleau, P; Goudier, MJ; Guastalla, JP; Kerbrat, P; Lortholary, A; Monnier, A; Montcuquet, P; Namer, M; Roché, H; Simon, H; Veyret, C; Walter, S | 1 |
| Chow, NH; Tsai, YS; Tzai, TS | 1 |
| Bafaloukos, D; Briasoulis, E; Dafni, U; Dimitrakakis, K; Dimopoulos, AM; Fountzilas, G; Gogas, H; Kalofonos, HP; Karanikiotis, C; Karina, M; Linardou, H; Makrantonakis, P; Markopoulos, C; Papadimitriou, C; Papakostas, P; Pectasides, D; Pisanidis, N; Polichronis, A; Samantas, E; Skarlos, D; Stathopoulos, GP; Tzorakoeleftherakis, E; Varthalitis, I; Xiros, N | 1 |
| Lehoczky, O; Pulay, T | 1 |
| Bacigalupo, A; Benasso, M; Corvò, R; Gatteschi, B; Marcenaro, M; Ponzanelli, A; Ravetti, JL; Vigo, V | 1 |
| Berdel, WE; Diallo-Danebrock, R; Frick, M; Gluz, O; Harbeck, N; Herr, A; Jackisch, C; Kates, R; Kirchner, H; Lindemann, W; Metzner, B; Mohrmann, S; Nitz, UA; Poremba, C; Schütt, G; Ting, E; Werner, F | 1 |
| Bhattacharyya, M; Carpenter, R; Gallagher, CJ; Ryan, D; Vinnicombe, S | 1 |
| Jin, WR; Li, LF; Liu, ZB; Shao, ZM; Shen, ZZ; Xu, XJ; Zhao, Y | 1 |
| Farabegoli, G; Fruet, F; Martoni, A; Pannuti, F; Tomasi, L | 1 |
| Amato, C; Callari, A; Cannata, G; Cipolla, C; Cusimano, MP; Garascia, C; Gebbia, N; Gebbia, V; Latteri, MA; Testa, A | 1 |
| Hsu, CY; Jan, JS; Lin, JC | 1 |
| Akesson, M; Andersson, H; Friberg, LG; Horvath, G; Johansson, O; Westberg, R | 1 |
| Botti, C; Cavaliere, R; Cognetti, F; Lopez, M; Scinto, AF; Vici, P | 1 |
| Algeri, R; Bella, M; Cocconi, G; De Lisi, V; Di Costanzo, F; Luppi, G; Mazzocchi, B; Rodinò, C; Soldani, M; Zironi, S | 1 |
| Bastert, G; Huober, J; Junkermann, H; Kaufmann, M; Leppien, G; Otto, HF; Schmid, H; Sinn, HP | 1 |
| Fukumoto, M; Hayashi, H; Kawabata, K; Masai, Y; Nio, M; Nio, Y; Sato, M; Shiraishi, T; Tseng, CC; Tsubono, M | 1 |
| Allum, WH; Baum, M; Bonnefoi, H; Ebbs, S; O'Brien, ME; Powles, TJ; Seymour, MT; Smith, IE | 1 |
| Bertelli, G; Pronzato, P; Vaira, F; Vigani, A | 1 |
| Biganzoli, L; Caraci, P; Gebbia, V; Iirillo, A; Maiorino, L | 1 |
| Bonnefoi, H; Smith, IE | 1 |
| Aravantinos, G; Beer, M; Fountzilas, G; Gennatas, K; Karpathios, S; Klouvas, G; Konstantaras, C; Kosmidis, P; Linardou, H; Makrantonakis, P; Mylonakis, N; Pavlidis, N; Skarlos, DV | 1 |
| Klonaris, C; Kosmas, C; Kosmidis, P; Lisaios, B; Mandrekois, D; Mylonakis, N; Sakelaropoulos, N; Soumilas, A; Tentas, K; Tsavaris, NB; Tsetis, A | 1 |
| Bertelsen, K; Gadeberg, CC; Havsteen, H; Jacobsen, A; Kamby, C; Sandberg, E; Sengeløv, L | 1 |
| Cunningham, D; Findlay, M; Harper, P; Hickish, T; Hill, A; Hughes, M; Iveson, T; Joffe, JK; Mansi, J; Meehan, M; Nicolson, M; Norman, A; O'Brien, M; Oates, J; Scarffe, JH; Underhill, C; Wardley, A; Watson, M; Webb, A | 1 |
| Alken, P; Köhrmann, KU; Kreukler, C; Siegsmund, MJ; Stendler, A | 1 |
| Bouaziz, M; Boudaya, M; Daoud, J; Drira, MM; Elloumi, M; Frikha, M; Ghorbel, A; Jlidi, R; Kechaou, MS; Souissi, T | 1 |
| Brambs, HJ; Görich, J; Kreienberg, R; Rieber, A; Rosenthal, H; Tomczak, R; Zeitler, H | 1 |
| Athanassiou, A; Dimitriades, M; Kostopoulou, M; Mylonakis, A; Papadopoulou, M; Pectasides, D; Triantafillis, D; Varthalitis, J | 1 |
| Choy, D; Chua, DT; Kwong, DL; Leong, L; Lo, M; Sham, JS; Tai, KS; Wu, PM; Yung, A | 1 |
| Chang, HT; Mok, KT; Tzeng, WS | 1 |
| Andersson, H; Horvath, G | 1 |
| Cerra, M; D'Aiuto, G; De Marco, MR; De Matteis, A; Frezza, P; Iannuzzo, M; Labonia, V; Landi, G; Montella, M; Oliviero, P | 1 |
| Barni, S; Battelli, N; Casaretti, R; Cascinu, S; Catalano, G; Cellerino, R; Comella, G; Frontini, L; Labianca, R; Pirovano, M; Zonato, S | 1 |
| Alonso, S; Armand, JP; Chouaki, N; Cortès-Funes, H; Cvitkovic, E; Fandi, A; Hasbini, A; Lianes, P; Mahjoubi, R; Raymond, E; Taamma, A | 1 |
| Armand, JP; Azli, N; Chouaki, N; Couteau, C; Cvitkovic, E; Fandi, A; Hasbini, A; Taamma, A; Wibault, P | 1 |
| Anderson, SH; Hudson-Peacock, M; Muller, AF | 1 |
| Carder, P; Gooi, J; Nishikawa, H; Wilson, J | 1 |
| A'Hern, RP; Barton, D; Blake, P; Gore, ME; Gregory, RK; Hill, ME; Johnston, SR; Moore, J; Shephard, J | 1 |
| Cree, IA; Crohns, C; Felber, M; Hepp, H; Konecny, G; Kurbacher, C; Lude, S; Pegram, M; Untch, M | 1 |
| Danenberg, PV; Kornmann, M; Leder, GH; Link, KH; Pillasch, J | 1 |
| Casella, G; Costanzo, R; De Placido, G; De Vivo, R; Iodice, F; Perrone, F; Pignata, S; Ricchi, P; Tramontana, F; Tramontana, S; Varriale, E; Vernaglia, A | 1 |
| Bolis, G; Chevallier, B; Kobierska, A; Pawinski, A; Vermorken, JB; Zanaboni, F | 1 |
| Benasso, M; Corvò, R; D'Amico, M; Guarneri, D; Numico, G; Pallestrini, E; Ricci, I; Rosso, R; Sanguineti, G; Santelli, A; Vitale, V | 1 |
| Harper, PG; Karapetis, CS; Strickland, AH; Yip, D | 1 |
| Cosio, S; Fanucchi, A; Gabriele, A; Gadducci, A; Landoni, F; Maggino, T; Rossi, R; Sartori, E; Tisi, G; Zola, P | 1 |
| Cunningham, D; Hill, M; Norman, A; Tebbutt, NC | 1 |
| Hyun, JH; Jeen, YT; Kim, BS; Kim, CS; Kim, JS; Kim, YH; Mok, YJ; Shin, SW; Yoon, SY | 1 |
| Airoldi, M; Bumma, C; De Crescenzo, A; Gabriele, AM; Marchionatti, S; Pedani, F; Rosti, G; Succo, G | 1 |
| Cowling, M; Harper, PG; Karapetis, CS; Ryder, K; Strickland, A; Virik, K; Yip, D | 1 |
| Ala-Eddine, C; Degardin, M; Kouto, H; Penel, N | 1 |
| Arnone, S; Cerullo, G; Dal Pozzo, C; Fornarola, V; Montanari, F; Suprani, G; Voce, S | 1 |
| Cavanagh, D; Franklin, EW; Harry, DS; Homesley, HD; Hoogstraten, B; Lovelace, JV; Nahhas, WA; O'Toole, RV; Smith, JJ | 1 |
| Cunningham, D; Husband, JE; MacVicar, D; Menzies-Gow, N; Taylor, R | 1 |
| Pummer, K | 1 |
| Chang, AY; Chen, KY; Jame, JM; Law, CK; Li, WY; Lin, CZ; Zen, HG | 1 |
| Hryniuk, WM | 1 |
| Ali, NM; Eissa, S; Elattar, I; Elsebai, I; Gad el Mawla, N; Habboubi, N; Hamza, MR; Khaled, H; Magrath, I; Mansour, MA | 1 |
| Amadori, D; Dollbaum, C; Hackett, AJ; Hiller, A; Lippman, M; Mayall, B; Smith, HS; Swain, S; Volpi, A; Zoli, W | 1 |
| Hemmer, J | 1 |
| Airoldi, M; Brando, V; Gabriele, P; Giordano, C; Pedani, F | 1 |
| Antila, K; Eksborg, S; Stendahl, U | 1 |
| Chang, SP; Chen, KY; Hu, OY; Jame, JM | 1 |
| Bono, AV; De Pauw, M; Fosså, SD; Jones, WG; Klijn, JG; Sylvester, R | 1 |
3 review(s) available for epirubicin and Carcinoma, Anaplastic
| Article | Year |
|---|---|
Partial hepatectomy for liver metastases from nasopharyngeal carcinoma: a comparative study and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Epirubicin; Ethiodized Oil; Female; Follow-Up Studies; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Mitomycin; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate | 2014 |
Preclinical models in electrochemotherapy: the role of veterinary patients.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Cat Diseases; Cats; Cisplatin; Dog Diseases; Dogs; Drug Evaluation, Preclinical; Electrochemotherapy; Epirubicin; Head and Neck Neoplasms; Melanoma; Mitoxantrone; Neoplasms; Quinazolines; Sarcoma; Thiophenes | 2012 |
Recall phenomenon following epirubicin.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Arm; Breast Neoplasms; Carcinoma; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Extravasation of Diagnostic and Therapeutic Materials; Female; Fluorouracil; Humans; Lymphatic Metastasis; Middle Aged | 1999 |
59 trial(s) available for epirubicin and Carcinoma, Anaplastic
| Article | Year |
|---|---|
Efficacy of a global supportive skin care programme with hydrotherapy after non-metastatic breast cancer treatment: A randomised, controlled study.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Emollients; Epirubicin; Female; Fluorouracil; Gonadotropin-Releasing Hormone; Hand-Foot Syndrome; Humans; Hydrotherapy; Hyperpigmentation; Lymphedema; Manual Lymphatic Drainage; Massage; Mastectomy; Middle Aged; Neoadjuvant Therapy; Pruritus; Quality of Life; Radiodermatitis; Radiotherapy, Adjuvant; Skin Care; Skin Diseases; Tamoxifen; Taxoids | 2018 |
Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma; Cyclophosphamide; Drug Therapy, Combination; Epirubicin; Female; Fluorouracil; Humans; Inflammatory Breast Neoplasms; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Treatment Outcome; Triple Negative Breast Neoplasms | 2013 |
Brachytherapy boost in loco-regionally advanced nasopharyngeal carcinoma: a prospective randomized trial of the International Atomic Energy Agency.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma; Chemoradiotherapy, Adjuvant; Cisplatin; Doxorubicin; Epirubicin; Female; Follow-Up Studies; Humans; International Agencies; Male; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Nuclear Energy; Prognosis; Prospective Studies; Radiation Injuries; Radiotherapy Dosage; Survival Rate | 2014 |
Clinical and microarray analysis of breast cancers of all subtypes from two prospective preoperative chemotherapy studies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; RNA, Messenger; Taxoids; Tissue Array Analysis; Transcriptome; Trastuzumab; Treatment Outcome; Young Adult | 2016 |
Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Methotrexate; Middle Aged; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Taxoids; Treatment Outcome | 2009 |
Preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) improves prognosis in locally advanced breast cancer patients: an update of the Southern Italy Cooperative Oncology Group (SICOG) randomised trial 9908.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cisplatin; Combined Modality Therapy; Disease Progression; Drug Administration Schedule; Epirubicin; Etoposide; Female; Follow-Up Studies; Humans; Italy; Middle Aged; Paclitaxel; Preoperative Care; Taxoids | 2010 |
Bacillus Calmette-Guérin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study.
Topics: Administration, Intravesical; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carcinoma; Chemotherapy, Adjuvant; Cystectomy; Disease Progression; Disease-Free Survival; Epirubicin; Female; Humans; Interferon alpha-2; Interferon-alpha; Kaplan-Meier Estimate; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Prospective Studies; Recombinant Proteins; Risk Assessment; Risk Factors; Scandinavian and Nordic Countries; Time Factors; Treatment Outcome; Tumor Burden; Urinary Bladder Neoplasms | 2010 |
Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Celecoxib; Cell Separation; Cyclophosphamide; Docetaxel; Early Detection of Cancer; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplastic Cells, Circulating; Pyrazoles; Sulfonamides; Survival Analysis; Taxoids; Time Factors; Trastuzumab; Young Adult | 2010 |
Comparison of the efficacy of single or double intravesical epirubicin instillation in the early postoperative period to prevent recurrences in non-muscle-invasive urothelial carcinoma of the bladder: prospective, randomized multicenter study.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma; Disease-Free Survival; Epirubicin; Female; Follow-Up Studies; Humans; Male; Middle Aged; Postoperative Period; Recurrence; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2010 |
Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease Progression; Docetaxel; Drug Administration Schedule; Epirubicin; Feasibility Studies; Humans; Infusions, Intravenous; Male; Middle Aged; Orchiectomy; Prednisone; Prostatic Neoplasms; Taxoids; Treatment Failure | 2011 |
Dose-tailoring of FEC adjuvant chemotherapy based on leukopenia is feasible and well tolerated. Toxicity and dose intensity in the Scandinavian Breast Group phase 3 adjuvant Trial SBG 2000-1.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Cyclophosphamide; Dose-Response Relationship, Drug; Epirubicin; Feasibility Studies; Female; Fluorouracil; Humans; Individuality; Leukopenia; Mastectomy; Maximum Tolerated Dose; Middle Aged; Precision Medicine; Scandinavian and Nordic Countries; Severity of Illness Index; Treatment Outcome | 2011 |
Tailored chemotherapy doses based on toxicity in breast cancer result in similar quality of life values, irrespective of given dose levels.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Humans; Individuality; Middle Aged; Precision Medicine; Quality of Life; Reference Values; Research Design; Surveys and Questionnaires | 2011 |
Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: a randomized phase II study conducted by the Hellenic Cooperative Oncology Group (HeC
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma; Chemoradiotherapy; Cisplatin; Epirubicin; Female; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Ki-67 Antigen; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Paclitaxel; Prognosis; Proportional Hazards Models; Tumor Suppressor Protein p53; Young Adult | 2012 |
Apoptosis gene signature of Survivin and its splice variant expression in breast carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Gene Expression Profiling; Humans; Inhibitor of Apoptosis Proteins; Middle Aged; Mutation; Neoplasm Proteins; Protein Isoforms; Reverse Transcriptase Polymerase Chain Reaction; Survivin; Tumor Suppressor Protein p53 | 2011 |
A multicenter phase III prospective randomized trial of high-dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node-positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study.
Topics: Adult; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Italy; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Prospective Studies; Survival Analysis; Taxoids | 2012 |
A phase I study of ixabepilone in combination with epirubicin in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Dose-Response Relationship, Drug; Epirubicin; Epothilones; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Treatment Outcome | 2012 |
High-dose epirubicin and cisplatin in locally advanced undifferentiated nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoadjuvant Therapy; Treatment Outcome | 2002 |
Escalating doses of paclitaxel and epirubicin in combination with cisplatin in advanced ovarian epithelial carcinoma: a phase I-II study.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antiemetics; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Male; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Survival Analysis | 2003 |
Randomized, controlled, multicenter phase III trial of standard-dose fluorouracil-epirubicin-cyclophosphamide (FEC), compared with time-intensive FEC (FEC-G) and mitoxantrone-methotrexate-mitomycin C (MMM-G) in metastatic breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Disease Progression; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Survival Analysis | 2003 |
Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian Collaborative Study from the Mario Negri Institute,
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease Progression; Epirubicin; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Survival Analysis; Treatment Outcome | 2004 |
Expression of endothelin-A-receptor predicts unfavourable response to neoadjuvant chemotherapy in locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Cyclophosphamide; Drug Resistance, Neoplasm; Endothelin-1; Epirubicin; Female; Gene Expression Profiling; Humans; Immunohistochemistry; Middle Aged; Neoadjuvant Therapy; Predictive Value of Tests; Receptor, Endothelin A; Receptor, Endothelin B; Sensitivity and Specificity; Treatment Outcome | 2004 |
Single-agent epirubicin as primary chemotherapy in T2-T3, N0-N2, M0 breast carcinoma: 6-year follow-up.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Carcinoma; Disease-Free Survival; Epirubicin; Female; Follow-Up Studies; Humans; Italy; Lymphatic Metastasis; Mastectomy, Modified Radical; Mastectomy, Segmental; Middle Aged; Treatment Outcome | 2004 |
Contrast enhanced magnetic resonance imaging underestimates residual disease following neoadjuvant docetaxel based chemotherapy for breast cancer.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Contrast Media; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Magnetic Resonance Imaging; Mastectomy; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Prospective Studies; Taxoids | 2004 |
Interim analysis of a phase II trial of cyclophosphamide, epirubicin and 5-fluorouracil (CEF) followed by docetaxel as preoperative chemotherapy for early stage breast carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Taxoids; Treatment Outcome | 2005 |
Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Epirubicin; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Middle Aged; Paclitaxel; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Risk Assessment; Risk Factors; Sensitivity and Specificity; Treatment Outcome | 2005 |
How reliable is MRI for predicting extent of residual breast cancer with different primary medical therapies?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Predictive Value of Tests; Prospective Studies; Reproducibility of Results; Taxoids | 2005 |
Epirubicin, cyclophosphamide and weekly paclitaxel as neoadjuvant chemotherapy for stage II and III breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Humans; Infusions, Intravenous; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Treatment Outcome | 2006 |
Telomerase activity, estrogen receptors (alpha, beta), Bcl-2 expression in human breast cancer and treatment response.
Topics: Adult; Aged; Breast Neoplasms; Carcinoma; Cyclophosphamide; Epirubicin; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Fluorouracil; HeLa Cells; Humans; Middle Aged; Proto-Oncogene Proteins c-bcl-2; Telomerase; Treatment Outcome | 2006 |
A randomized phase II trial comparing preoperative plus perioperative chemotherapy with preoperative chemotherapy in patients with locally advanced breast cancer.
Topics: Adult; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Humans; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Perioperative Care; Receptor, ErbB-2; Survival Analysis | 2006 |
Epirubicin-vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Cyclophosphamide; Disease Progression; Epirubicin; Female; Fluorouracil; France; Humans; Lymphatic Metastasis; Mastectomy; Middle Aged; Survival Analysis; Vinblastine; Vinorelbine | 2007 |
Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00.
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Epirubicin; Estrogens; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Lymphatic Metastasis; Mastectomy; Methotrexate; Middle Aged; Neoplasms, Hormone-Dependent; Neoplasms, Second Primary; Paclitaxel; Peripheral Nervous System Diseases; Tamoxifen | 2008 |
Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Epirubicin; Estrogens; Female; Fluorouracil; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Kaplan-Meier Estimate; Methotrexate; Middle Aged; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Proportional Hazards Models; Retrospective Studies; Single-Blind Method; Survival Analysis; Tamoxifen; Treatment Outcome | 2008 |
Using MRI to plan breast-conserving surgery following neoadjuvant chemotherapy for early breast cancer.
Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Early Diagnosis; Epirubicin; Female; Humans; Magnetic Resonance Imaging; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Sensitivity and Specificity; Treatment Outcome | 2008 |
A phase I-II study of cyclophosphamide, epidoxorubicin, levofolinic acid/5-fluorouracil and recombinant human granulocyte colony stimulating factor in metastatic breast carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Leucovorin; Leukopenia; Middle Aged; Recombinant Proteins; Treatment Outcome | 1994 |
Neoadjuvant chemotherapy for advanced nasopharyngeal carcinoma.
Topics: Actuarial Analysis; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Epirubicin; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Middle Aged; Nasopharyngeal Neoplasms; Remission Induction; Survival Analysis | 1995 |
Carboplatin in combination with epirubicin and cyclophosphamide in patients with advanced ovarian cancer. A phase II study.
Topics: Adult; Aged; Ambulatory Care; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cyclophosphamide; Disease Progression; Epirubicin; Female; Follow-Up Studies; Humans; Laparotomy; Leukopenia; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Ovarian Neoplasms; Remission Induction; Reoperation; Survival Rate; Thrombocytopenia; Vomiting | 1995 |
Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Mitomycin; Prospective Studies; Remission Induction; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 1994 |
A phase II study of 5-fluorouracil, cisplatin, and 4'-epirubicin in the treatment of advanced solid cancers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Male; Middle Aged; Remission Induction; Survival Analysis | 1993 |
Phase II study of continuous infusional 5-fluorouracil with epirubicin and carboplatin (instead of cisplatin) in patients with metastatic/locally advanced breast cancer (infusional ECarboF): a very active and well-tolerated outpatient regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis | 1996 |
A feasibility study of accelerated polychemotherapy with cisplatin, epidoxorubicin and cyclophosphamide (PEC) in advanced ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma; Cisplatin; Cyclophosphamide; Dose-Response Relationship, Drug; Endometrial Neoplasms; Epirubicin; Feasibility Studies; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukocyte Count; Neoplasm Staging; Ovarian Neoplasms; Platelet Count | 1996 |
Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV(> or = N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Epirubicin; Female; Humans; Male; Mouth Mucosa; Nasopharyngeal Neoplasms; Neoplasm Staging; Stomatitis; Treatment Outcome | 1996 |
Carboplatin alone compared with its combination with epirubicin and cyclophosphamide in untreated advanced epithelial ovarian cancer: a Hellenic co-operative oncology group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cyclophosphamide; Disease Progression; Disease-Free Survival; Epirubicin; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Prognosis; Prospective Studies; Remission Induction; Survival Analysis; Survival Rate | 1996 |
5-Fluorouracil, epirubicin, and mitomycin C versus 5-fluorouracil, epirubicin, mitomycin C, and leucovorin in advanced gastric carcinoma. A randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Epirubicin; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Stomach Neoplasms; Survival Rate | 1996 |
A phase 2 study with epirubicin as second-line treatment of patients with advanced epithelial ovarian cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Carcinoma; Disease Progression; Epirubicin; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Treatment Outcome | 1996 |
Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Costs and Cost Analysis; Doxorubicin; Drug Costs; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Methotrexate; Middle Aged; Prospective Studies; Quality of Life; Stomach Neoplasms; Survival Rate | 1997 |
Multimodal treatment strategy for locally advanced breast cancer.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma; Combined Modality Therapy; Drug Administration Schedule; Epirubicin; Female; Humans; Mastectomy, Modified Radical; Middle Aged; Neoadjuvant Therapy; Prognosis; Radiotherapy, Adjuvant; Receptors, Estrogen; Survival Analysis; Tamoxifen; Treatment Outcome | 1998 |
Intensive weekly chemotherapy is not effective in advanced pancreatic cancer patients: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carcinoma; Cisplatin; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Lenograstim; Leucovorin; Male; Middle Aged; Pain; Palliative Care; Pancreatic Neoplasms; Recombinant Proteins; Survival Analysis; Treatment Outcome | 1999 |
Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Hematologic Diseases; Humans; Lymphatic Metastasis; Male; Middle Aged; Mitomycins; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Radiotherapy, Adjuvant; Survival Rate | 1999 |
Phase II trial of chemotherapy with 5-fluorouracil, bleomycin, epirubicin, and cisplatin for patients with locally advanced, metastatic, or recurrent undifferentiated carcinoma of the nasopharyngeal type.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Cisplatin; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Radiotherapy; Survival Rate; Treatment Outcome | 1999 |
A phase I study of gemcitabine and epirubicin for the treatment of platinum-resistant or refractory advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epirubicin; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Treatment Outcome | 2000 |
A phase II study of high-dose epirubicin in ovarian cancer patients previously treated with cisplatin. EORTC Gynecological Cancer Cooperative Group.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Carcinoma; Cisplatin; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Middle Aged; Ovarian Neoplasms; Treatment Outcome | 2000 |
Induction chemotherapy followed by alternating chemo-radiotherapy in stage IV undifferentiated nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Prospective Studies; Remission Induction; Survival Rate | 2000 |
Adjuvant chemotherapy for gastro-oesophageal cancer with epirubicin, cisplatin and fluorouracil: a single-centre experience.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Prognosis; Retrospective Studies; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2001 |
Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Drug Administration Schedule; Drug Tolerance; Epirubicin; Female; Humans; Leucovorin; Male; Middle Aged; Stomach Neoplasms; Tegafur; Treatment Outcome; Uracil | 2001 |
Phase I-II pilot study on the efficacy and tolerability of neoadjuvant chemotherapy (Rescue M-VEC) and preoperative radiation therapy for infiltrating bladder cancer: results of an 18-month follow-up.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Cobalt Radioisotopes; Combined Modality Therapy; Cystectomy; Epirubicin; Evaluation Studies as Topic; Female; Humans; Male; Methotrexate; Middle Aged; Pilot Projects; Preoperative Care; Radioisotope Teletherapy; Remission Induction; Urinary Bladder Neoplasms; Vinblastine | 1992 |
Randomized comparison of cisplatin plus epirubicin or doxorubicin for advanced epithelial ovarian carcinoma. A multicenter trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Double-Blind Method; Doxorubicin; Epirubicin; Female; Humans; Middle Aged; Ovarian Neoplasms; Prospective Studies; Survival Analysis | 1992 |
Epirubicin plus flutamide and orchidectomy in previously untreated advanced prostatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined Modality Therapy; Epirubicin; Flutamide; Follow-Up Studies; Humans; Male; Orchiectomy; Prognosis; Prostatic Neoplasms; Survival Rate | 1991 |
A randomized pilot study of high-dose epirubicin as neoadjuvant chemotherapy in the treatment of cancer of the bilharzial bladder.
Topics: Adult; Carcinoma; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Combined Modality Therapy; Epirubicin; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Postoperative Complications; Schistosomiasis; Survival Rate; Urinary Bladder Neoplasms | 1991 |
Pharmacokinetics of 4' epi-adriamycin after morning and afternoon intravenous administration.
Topics: Aged; Analysis of Variance; Biological Availability; Carcinoma; Circadian Rhythm; Epirubicin; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Random Allocation; Sarcoma; Uterine Neoplasms | 1989 |
64 other study(ies) available for epirubicin and Carcinoma, Anaplastic
| Article | Year |
|---|---|
Recombinant Human Lactoferrin Augments Epirubicin Chemotherapy in Solid Ehrlich Carcinoma Bearing Mice.
Topics: Animals; Breast Neoplasms; Carcinoma; Epirubicin; Female; Humans; Interleukin-18; Lactoferrin; Mice; Recombinant Proteins | 2023 |
Successful Treatment of Therapy-related Acute Promyelocytic Leukemia with All-trans-retinoic acid Following Epirubicin for Hepatocellular Carcinoma and Docetaxel and Pembrolizumab Therapies for Lung Carcinoma: A Triple Malignancy Case.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Hepatocellular; Docetaxel; Epirubicin; Humans; Leukemia, Promyelocytic, Acute; Liver Neoplasms; Lung Neoplasms; Male; Neoplasms, Multiple Primary; Treatment Outcome; Tretinoin | 2020 |
Epirubicin suppresses proliferative and metastatic potential by downregulating transforming growth factor-β-induced expression in urothelial carcinoma.
Topics: Carcinoma; Cell Line, Tumor; Cell Movement; Cell Proliferation; Down-Regulation; Epirubicin; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; RNA, Messenger; Transforming Growth Factor beta; Up-Regulation; Urologic Neoplasms; Urothelium | 2018 |
Lymphoepithelioma-Like Carcinoma of the Esophagus: A Rare Tumor.
Topics: Antineoplastic Agents; Biopsy; Capecitabine; Carcinoma; Cisplatin; Epirubicin; Esophageal Neoplasms; Esophagectomy; Female; Humans; Immunohistochemistry; Middle Aged; Treatment Outcome | 2017 |
Carboplatin and epirubicin combination therapy for advanced malignant epithelial skin tumors: Retrospective study of six patients.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Epirubicin; Female; Humans; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Skin Neoplasms; Treatment Outcome | 2018 |
Effects of adjuvant chemotherapy in T1N0M0 triple-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Mastectomy; Mastectomy, Segmental; Middle Aged; Multivariate Analysis; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Retrospective Studies; Taxoids; Triple Negative Breast Neoplasms | 2019 |
The investigation of a traditional Chinese medicine, Guizhi Fuling Wan (GFW) as an intravesical therapeutic agent for urothelial carcinoma of the bladder.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 2; Cisplatin; Cyclin-Dependent Kinase Inhibitor p21; Drugs, Chinese Herbal; Epirubicin; Humans; Mitomycin; Phytotherapy; Protein Serine-Threonine Kinases; Sincalide; Urinary Bladder; Urinary Bladder Neoplasms; Urothelium | 2013 |
Eukaryotic translation initiation factor 4E (eIF4E) expression is associated with breast cancer tumor phenotype and predicts survival after anthracycline chemotherapy treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Cyclophosphamide; Cytarabine; Doxorubicin; Epirubicin; Eukaryotic Initiation Factor-4E; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Proteins; Paraffin Embedding; Phenotype; Prognosis; Protein Biosynthesis; Tissue Array Analysis; Treatment Outcome; Triple Negative Breast Neoplasms | 2013 |
Metastatic cutaneous apocrine carcinoma of the axilla successfully treated using systemic chemotherapy with i.v. epirubicin and cyclophosphamide followed by oral fluorinated pyrimidine.
Topics: Adult; Antineoplastic Agents; Axilla; Carcinoma; Cyclophosphamide; Drug Combinations; Epirubicin; Humans; Male; Oxonic Acid; Sweat Gland Neoplasms; Tegafur | 2014 |
The Impact of Positive Margins on Outcome Among Patients With Gastric Cancer Treated With Radiation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Epirubicin; Female; Gastrectomy; Humans; Lymphatic Metastasis; Male; Margins of Excision; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Proportional Hazards Models; Radiotherapy, Adjuvant; Retrospective Studies; Risk Factors; Stomach Neoplasms; Survival Rate | 2016 |
Epirubicin loading in poly(butyl cyanoacrylate) nanoparticles manifests via altered intracellular localization and cellular response in cervical carcinoma (HeLa) cells.
Topics: Apoptosis; Carcinoma; Caspase 3; Cell Line, Tumor; Chemistry, Pharmaceutical; Drug Carriers; Drug Delivery Systems; Enbucrilate; Endocytosis; Epirubicin; Female; HeLa Cells; Humans; Nanoparticles; Tumor Suppressor Protein p53; Uterine Cervical Neoplasms | 2016 |
Has serum CA 125 assay at the time of relapse a prognostic relevance for patients with recurrent ovarian carcinoma after primary cytoreduction and platinum- and paclitaxel-based chemotherapy?
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; CA-125 Antigen; Carboplatin; Carcinoma; Carcinoma, Endometrioid; Cohort Studies; Cytoreduction Surgical Procedures; Epirubicin; Female; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies | 2016 |
Response to apatinib in chemotherapy-failed advanced spindle cell breast carcinoma.
Topics: Albumin-Bound Paclitaxel; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Breast; Carcinoma; Chemotherapy, Adjuvant; Circulating Tumor DNA; Cisplatin; Cyclophosphamide; Disease Progression; Drug Resistance, Neoplasm; Epirubicin; ErbB Receptors; Female; Hand-Foot Syndrome; High-Throughput Nucleotide Sequencing; Humans; Hypertension; Lung Neoplasms; Mastectomy, Modified Radical; Middle Aged; Mutation; Neovascularization, Pathologic; Positron Emission Tomography Computed Tomography; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sequence Analysis, DNA; Thoracic Neoplasms; Treatment Failure; Triple Negative Breast Neoplasms | 2016 |
Usefulness of CTC and DTC-BM Detection for Adjuvant Therapy Effects and Prognosis Prediction in Early Breast Carcinoma: Results of 8-11 Years of Follow-up Evaluation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bone Marrow; Bone Neoplasms; Breast Neoplasms; Carcinoma; Cell Count; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Liver Neoplasms; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Prognosis; Tamoxifen; Treatment Outcome | 2017 |
Tender nodules on the palms and soles after chemotherapy.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma; Drug-Related Side Effects and Adverse Reactions; Epirubicin; Erythema; Foot; Hand; Humans; Ifosfamide; Male; Pleural Neoplasms; Treatment Outcome | 2008 |
Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Hematologic Diseases; Humans; Hypertension; Infusions, Intravenous; Letrozole; Mastectomy; Middle Aged; Nitriles; Paclitaxel; Prognosis; Proteinuria; Radiotherapy, Adjuvant; Triazoles | 2009 |
What is the optimal treatment strategy for T1 bladder tumors?
Topics: Administration, Intravesical; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carcinoma; Cystectomy; Disease Progression; Disease-Free Survival; Epirubicin; Humans; Interferon alpha-2; Interferon-alpha; Neoplasm Recurrence, Local; Neoplasm Staging; Practice Guidelines as Topic; Recombinant Proteins; Reoperation; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Tumor Burden; Urinary Bladder Neoplasms | 2010 |
Preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) improves prognosis: how much is it true?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Epirubicin; Etoposide; Female; Humans; Paclitaxel; Preoperative Care; Prognosis; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2010 |
[Cerebral radionecrosis after irradiation of a cancer of the cavum].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Injury, Chronic; Brain Stem; Carcinoma; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Diagnosis, Differential; Epirubicin; Female; Gait Disorders, Neurologic; Humans; Hypesthesia; Magnetic Resonance Imaging; Nasopharyngeal Neoplasms; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paresis; Radiation Injuries; Temporal Lobe | 2009 |
[Pediatric nasopharyngeal carcinoma: Anatomoclinic aspects, therapeutic results and evolutive particularities].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Chemotherapy, Adjuvant; Child; Cisplatin; Cobalt Radioisotopes; Combined Modality Therapy; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Nasopharyngeal Neoplasms; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Radioisotope Teletherapy; Radiotherapy, Conformal; Retrospective Studies; Treatment Outcome; Xerostomia; Young Adult | 2010 |
[Clinical experience in the treatment of ovarian carcinoma and the role of the nurse during the hemotherapy].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Epirubicin; Female; Humans; Middle Aged; Nurse-Patient Relations; Ovarian Neoplasms; Paclitaxel; Young Adult | 2009 |
Optimizing dose-dense regimens for early-stage breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Erythropoietin; Female; Humans; Mastectomy; Multicenter Studies as Topic; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Recombinant Proteins; Survival Analysis | 2010 |
Smoking status is a risk factor for recurrence after transurethral resection of non-muscle-invasive bladder cancer.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma; Combined Modality Therapy; Epirubicin; Female; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Risk Factors; Sex Factors; Smoking; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Surgical Procedures | 2011 |
[Primary systemic therapy in breast cancer patients (2007-2010)].
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carcinoma; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular; Carcinoma, Medullary; Carcinoma, Papillary; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Mastectomy; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Neoplasm, Residual; Radiography; Retrospective Studies; Taxoids; Treatment Outcome | 2011 |
Cigarette smoking status at diagnosis and recurrence in intermediate-risk non-muscle-invasive bladder carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma; Combined Modality Therapy; Cystectomy; Disease-Free Survival; Epirubicin; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Proportional Hazards Models; Risk Factors; Smoking; Time Factors; Urinary Bladder Neoplasms | 2013 |
Multidrug resistance in ovarian cancer: comparing an immunocytochemical study and ATP-tumor chemosensitivity assay.
Topics: Adenosine Triphosphate; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers; Carcinoma; Cisplatin; Cyclophosphamide; Drug Resistance, Multiple; Drug Screening Assays, Antitumor; Epirubicin; Female; Genes, MDR; Humans; Immunohistochemistry; Middle Aged; Ovarian Neoplasms; Predictive Value of Tests; Prognosis; Survival | 2002 |
Secretory breast carcinoma--case report and review of the medical literature.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carcinoma; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Lymph Node Excision; Mastectomy; Radiotherapy, Adjuvant; Treatment Outcome | 2004 |
Antitumor effect of valorphin in vitro and in vivo: combined action with cytostatic drugs.
Topics: Adamantane; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Bone Marrow Cells; Breast Neoplasms; Carcinoma; Cell Proliferation; Drug Interactions; Epirubicin; Fibroblasts; Humans; Mice; Mice, Inbred BALB C; Survival; Tumor Cells, Cultured; Vincristine | 2005 |
Advanced stage thymomas and thymic carcinomas: results of multimodality treatments.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Epirubicin; Etoposide; Female; Humans; Male; Middle Aged; Myasthenia Gravis; Neoadjuvant Therapy; Radiotherapy, Adjuvant; Retrospective Studies; Survival Analysis; Thymoma; Thymus Neoplasms; Treatment Outcome | 2005 |
[Survival prospects of mesopharyngeal carcinoma patients treated primarily with intraarterial chemotherapy. A retrospective study].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Disease Progression; Epirubicin; Female; Humans; Infusions, Intra-Arterial; Leucovorin; Male; Methotrexate; Middle Aged; Pharyngeal Neoplasms; Retrospective Studies; Survival Analysis; Treatment Outcome; Vincristine | 2006 |
Reconstruction of an extensive chest wall defect using an external oblique myocutaneous flap following resection of an advanced breast carcinoma: report of a case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Carcinoma; Cyclophosphamide; Epirubicin; Female; Humans; Middle Aged; Odorants; Surgical Flaps | 2006 |
Does HER2 immunoreactivity provide prognostic information in locally advanced urothelial carcinoma patients receiving adjuvant M-VEC chemotherapy?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Epirubicin; Female; Follow-Up Studies; Humans; Immunohistochemistry; Lymphatic Metastasis; Male; Methotrexate; Middle Aged; Proportional Hazards Models; Receptor, ErbB-2; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium; Vinblastine | 2007 |
[Evaluation of second-line chemotherapies most often used in recurrent epithelial ovarian cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Middle Aged; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Topotecan; Treatment Outcome | 2007 |
Induction chemotherapy followed by alternating chemo-radiotherapy in non-endemic undifferentiated carcinoma of the nasopharynx: optimal compliance and promising 4-year results.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Epidemiologic Methods; Epirubicin; ErbB Receptors; Female; Fluorouracil; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Treatment Outcome; Young Adult | 2008 |
Integrated gene expression profile predicts prognosis of breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Proteins; Oligonucleotide Array Sequence Analysis; Prognosis; Proportional Hazards Models; RNA, Messenger; RNA, Neoplasm; Young Adult | 2009 |
4'-epi-doxorubicin in combination with cisplatin in advanced ovarian cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cystadenocarcinoma; Doxorubicin; Epirubicin; Female; Humans; Middle Aged; Ovarian Neoplasms | 1984 |
Prognostic value of lymph node metastases after neoadjuvant chemotherapy for large-sized operable carcinoma of the breast.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Epirubicin; Female; Follow-Up Studies; Humans; Lymph Node Excision; Lymphatic Metastasis; Mastectomy, Segmental; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Neoplasm Staging; Preoperative Care; Prognosis; Prospective Studies; Radiotherapy, Adjuvant; Remission Induction | 1995 |
[Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cell Division; Cell Survival; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Premedication | 1994 |
Thyroid cancer: different outcomes to chemotherapy according to tumour histology.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Carcinoma; Epirubicin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Thyroid Neoplasms; Treatment Outcome | 1995 |
How should cancer presenting as a malignant pleural effusion be managed?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bronchoscopy; Carcinoma; Cisplatin; Epirubicin; Female; Fluorouracil; Humans; Lung Neoplasms; Male; Middle Aged; Mitomycins; Neoplasms, Unknown Primary; Palliative Care; Pleural Effusion, Malignant; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome; Vinblastine | 1996 |
Enhanced in vitro cytotoxicity of idarubicin compared to epirubicin and doxorubicin in rat prostate carcinoma cells.
Topics: Animals; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma; Cell Division; Doxorubicin; Drug Resistance, Multiple; Epirubicin; Humans; Idarubicin; KB Cells; Lethal Dose 50; Male; Prostatic Neoplasms; Rats; Tumor Cells, Cultured | 1997 |
[Evaluation of tumoral and lymph node response to neoadjuvant chemotherapy in undifferentiated nasopharyngeal carcinoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Child; Cisplatin; Combined Modality Therapy; Epirubicin; Female; Humans; Lymphatic Metastasis; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Staging; Survival Analysis; Treatment Outcome | 1997 |
MRI of breast cancer: influence of chemotherapy on sensitivity.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Contrast Media; Cyclophosphamide; Edetic Acid; Epirubicin; False Negative Reactions; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Organometallic Compounds; Sensitivity and Specificity | 1997 |
CEA, CA 19-9, and CA-50 in monitoring gastric carcinoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Carcinoembryonic Antigen; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Epirubicin; Etoposide; Female; Humans; Incidence; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Palliative Care; Prognosis; Prospective Studies; Sensitivity and Specificity; Stomach Neoplasms; Treatment Outcome | 1997 |
Volumetric analysis of tumor extent in nasopharyngeal carcinoma and correlation with treatment outcome.
Topics: Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Dose Fractionation, Radiation; Epirubicin; Female; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Staging; Prognosis; Randomized Controlled Trials as Topic; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 1997 |
Induction intraarterial chemotherapy for T4 breast cancer through an implantable port-catheter system.
Topics: Adult; Aged; Ambulatory Care; Angiography, Digital Subtraction; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brachial Artery; Breast Neoplasms; Carcinoma; Catheterization, Peripheral; Catheters, Indwelling; Coloring Agents; Epirubicin; Feasibility Studies; Female; Humans; Injections, Intra-Arterial; Mammary Arteries; Mammography; Middle Aged; Mitomycin; Neoplasm Staging; Remission Induction; Subclavian Artery; Treatment Outcome; Ultrasonography, Mammary | 1997 |
Long-term chemotherapy of ovarian cancer: two case reports.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Fatal Outcome; Female; Follow-Up Studies; Humans; Liver Neoplasms; Long-Term Care; Medroxyprogesterone; Middle Aged; Ovarian Neoplasms; Ovariectomy; Pancreatic Neoplasms | 1998 |
Malignant acanthosis nigricans: potential role of chemotherapy.
Topics: Acanthosis Nigricans; Aged; Anal Canal; Antibiotics, Antineoplastic; Antimetabolites; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Epirubicin; Facial Dermatoses; Fluorouracil; Humans; Hyperpigmentation; Male; Stomach Neoplasms | 1999 |
Combining platinum, paclitaxel and anthracycline in patients with advanced gynaecological malignancy.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Doxorubicin; Epirubicin; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Pilot Projects; Treatment Outcome | 2000 |
Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Cyclophosphamide; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Epirubicin; Female; Humans; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Regression Analysis; Sensitivity and Specificity; Survival Analysis; Tumor Cells, Cultured | 2000 |
Theoretical considerations and in vitro concentration response studies with two human colorectal carcinoma cell lines. The rational experimental base for clinical studies in regional chemotherapy.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Carcinoma; Cisplatin; Colorectal Neoplasms; Doxorubicin; Epirubicin; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Melphalan; Mitomycin; Mitoxantrone; Tumor Cells, Cultured | 2000 |
Analysis of treatment failures and survival of patients with fallopian tube carcinoma: a cooperation task force (CTF) study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Epirubicin; Fallopian Tube Neoplasms; Female; Humans; Hysterectomy; Middle Aged; Neoplasm Staging; Ovariectomy; Reoperation; Retrospective Studies; Salpingostomy; Survival Rate; Treatment Failure | 2001 |
Standard chemotherapy for gastric carcinoma: is it a myth?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Doxorubicin; Epirubicin; Fluorouracil; Humans; Methotrexate; Stomach Neoplasms; Survival Rate; United Kingdom | 2001 |
Feasibility and long-term results of autologous PBSC transplantation in recurrent undifferentiated nasopharyngeal carcinoma.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Dose-Response Relationship, Drug; Epirubicin; Feasibility Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Transplantation, Autologous | 2001 |
Epirubicin, cisplatin, and prolonged or brief infusional 5-fluorouracil in the treatment of carcinoma of unknown primary site.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carcinoma; Cisplatin; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms, Unknown Primary; Patient Selection; Retrospective Studies; Survival Analysis; Treatment Outcome | 2001 |
[Tumor lysis syndrome with symptomatic hyperuricemia after a first chemotherapeutic treatment of undifferentiated carcinoma of the cavum].
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Cisplatin; Epirubicin; Humans; Male; Nasopharyngeal Neoplasms; Time Factors; Tomography, X-Ray Computed; Tumor Lysis Syndrome; Uric Acid | 2002 |
Intra-abdominal panniculitis can mimic recurrent stomach carcinoma.
Topics: Abdomen; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Diagnosis, Differential; Epirubicin; Fat Necrosis; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Panniculitis; Stomach Neoplasms | 1992 |
Nasopharyngeal carcinoma with bone marrow metastasis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma; Cisplatin; Combined Modality Therapy; Epirubicin; Female; Humans; Lymphatic Metastasis; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Radiotherapy Dosage; Survival Rate | 1991 |
What were the received dose intensities in the three arms?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans | 1991 |
Preliminary correlations of clinical outcome with in vitro chemosensitivity of second passage human breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cell Survival; Cisplatin; Daunorubicin; Doxorubicin; Epirubicin; Humans; In Vitro Techniques; Prognosis; Tumor Cells, Cultured; Vinblastine | 1990 |
Rapid in vitro bromodeoxyuridine labeling method for monitoring of therapy response in solid human tumors.
Topics: Antineoplastic Agents; Bromodeoxyuridine; Carcinoma; Cell Cycle; Cisplatin; Colony-Forming Units Assay; DNA, Neoplasm; Epirubicin; Flow Cytometry; Head and Neck Neoplasms; Humans; Mouth Neoplasms; Tumor Stem Cell Assay | 1990 |
Cisplatin, epirubicin and 5-fluorouracil combination chemotherapy for recurrent carcinoma of the salivary gland.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Adenoid Cystic; Cisplatin; Epirubicin; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Palliative Care; Salivary Gland Neoplasms | 1989 |
Pharmacokinetic and pharmacodynamic studies with 4'-epi-doxorubicin in nasopharyngeal carcinoma patients.
Topics: Adolescent; Adult; Carcinoma; Chromatography, High Pressure Liquid; Drug Evaluation; Epirubicin; Female; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Remission Induction; Time Factors | 1989 |
European Organization for Research and Treatment of Cancer (EORTC) phase II study of low-dose weekly epirubicin in metastatic prostate cancer.
Topics: Aged; Carcinoma; Dose-Response Relationship, Drug; Doxorubicin; Drug Evaluation; Epirubicin; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms | 1987 |